[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2019",
          "fs": "May 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078ig2UAA"
          },
          "Id": "a0P2P0000078ig2UAA",
          "Event_Date__c": "2019-05-27",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "May 2019",
          "Status_History__c": "a132P000000EB3fQAG"
        },
        "change": null
      }
    ],
    "dateString": "May 2019",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2020",
          "fs": "Oct 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078ig3UAA"
          },
          "Id": "a0P2P0000078ig3UAA",
          "Event_Date__c": "2020-10-13",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Oct 2020",
          "Status_History__c": "a132P000000EBMwQAO"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p>1.1.\u00a0\u00a0\u00a0\u00a0The Committee <strong>recommended</strong> that upadacitinib be funded for the treatment of moderate to severe rheumatoid arthritis in patients for whom treatment with current first-line biologic disease-modifying anti-rheumatic drugs (DMARDs) (adalimumab and/or etanercept) has not been adequate, as a second-line biologic/targeted treatment instead of currently funded second-line biologic DMARDs i.e. infliximab or rituximab, with a medium priority, subject to appropriate Special Authority criteria.</p><p>1.2.\u00a0\u00a0\u00a0\u00a0In making this recommendation, the Committee considered the high health need of this patient group for whom currently funded DMARD and biologic treatments fail or are intolerable; the evidence of benefit from upadacitinib in this population; the convenience of an oral formulation over current subcutaneous and intravenous treatments, which has the potential to help address access inequities e.g. for rural patients, and ease pressures on infusion services; and the requirement for a funded herpes zoster vaccine in this patient group.</p><p>1.3.\u00a0\u00a0\u00a0\u00a0The Committee considered that advice from the Rheumatology Subcommittee should be sought regarding upadacitinib for the treatment of RA, and in particular: whether there is evidence for the use of upadacitinib in children with juvenile idiopathic arthritis (JIA) and which particular types; the appropriate sequencing of upadacitinib and other treatments for RA; appropriate Special Authority criteria for upadacitinib for RA; and whether there is a class effect among JAK inhibitors in this setting.\u00a0</p><p><br></p>",
          "fs": "<p>1.1.\u00a0\u00a0\u00a0\u00a0The Committee <strong>recommended</strong> that upadacitinib be funded for the treatment of moderate to severe rheumatoid arthritis in patients for whom treatment with current first-line biologic disease-modifying anti-rheumatic drugs (DMARDs) (adalimumab and/or etanercept) has not been adequate, as a second-line biologic/targeted treatment instead of currently funded second-line biologic DMARDs i.e. infliximab or rituximab, with a medium priority, subject to appropriate Special Authority criteria.</p><p>1.2.\u00a0\u00a0\u00a0\u00a0In making this recommendation, the Committee considered the high health need of this patient group for whom currently funded DMARD and biologic treatments fail or are intolerable; the evidence of benefit from upadacitinib in this population; the convenience of an oral formulation over current subcutaneous and intravenous treatments, which has the potential to help address access inequities e.g. for rural patients, and ease pressures on infusion services; and the requirement for a funded herpes zoster vaccine in this patient group.</p><p>1.3.\u00a0\u00a0\u00a0\u00a0The Committee considered that advice from the Rheumatology Subcommittee should be sought regarding upadacitinib for the treatment of RA, and in particular: whether there is evidence for the use of upadacitinib in children with juvenile idiopathic arthritis (JIA) and which particular types; the appropriate sequencing of upadacitinib and other treatments for RA; appropriate Special Authority criteria for upadacitinib for RA; and whether there is a class effect among JAK inhibitors in this setting.\u00a0</p><p><br></p>",
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Medium",
          "fs": "Medium",
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf\" target=\"_blank\">PTAC meeting record</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf\" target=\"_blank\">PTAC meeting record</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2021",
          "fs": "May 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078ig4UAA"
          },
          "Id": "a0P2P0000078ig4UAA",
          "Event_Date__c": "2021-05-12",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf\" target=\"_blank\">PTAC meeting record</a></p>",
          "Outcome__c": "Medium",
          "Formatted_Date__c": "May 2021",
          "Published_Recommendation__c": "<p>1.1.\u00a0\u00a0\u00a0\u00a0The Committee <strong>recommended</strong> that upadacitinib be funded for the treatment of moderate to severe rheumatoid arthritis in patients for whom treatment with current first-line biologic disease-modifying anti-rheumatic drugs (DMARDs) (adalimumab and/or etanercept) has not been adequate, as a second-line biologic/targeted treatment instead of currently funded second-line biologic DMARDs i.e. infliximab or rituximab, with a medium priority, subject to appropriate Special Authority criteria.</p><p>1.2.\u00a0\u00a0\u00a0\u00a0In making this recommendation, the Committee considered the high health need of this patient group for whom currently funded DMARD and biologic treatments fail or are intolerable; the evidence of benefit from upadacitinib in this population; the convenience of an oral formulation over current subcutaneous and intravenous treatments, which has the potential to help address access inequities e.g. for rural patients, and ease pressures on infusion services; and the requirement for a funded herpes zoster vaccine in this patient group.</p><p>1.3.\u00a0\u00a0\u00a0\u00a0The Committee considered that advice from the Rheumatology Subcommittee should be sought regarding upadacitinib for the treatment of RA, and in particular: whether there is evidence for the use of upadacitinib in children with juvenile idiopathic arthritis (JIA) and which particular types; the appropriate sequencing of upadacitinib and other treatments for RA; appropriate Special Authority criteria for upadacitinib for RA; and whether there is a class effect among JAK inhibitors in this setting.\u00a0</p><p><br></p>",
          "Status_History__c": "a132P000000EBNQQA4"
        },
        "change": null
      }
    ],
    "dateString": "Oct 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2021",
          "fs": "May 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078ig5UAA"
          },
          "Id": "a0P2P0000078ig5UAA",
          "Event_Date__c": "2021-05-12",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "May 2021",
          "Status_History__c": "a132P000000EB3kQAG"
        },
        "change": null
      }
    ],
    "dateString": "May 2021",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  }
]